You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKesson
Dow
Mallinckrodt
Colorcon

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

Amring Pharms Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for AMRING PHARMS, and what generic alternatives to AMRING PHARMS drugs are available?

AMRING PHARMS has eleven approved drugs.

There are eight US patents protecting AMRING PHARMS drugs.

There are eight patent family members on AMRING PHARMS drugs in two countries and nineteen supplementary protection certificates in nine countries.

Summary for Amring Pharms
International Patents:8
US Patents:8
Tradenames:10
Ingredients:10
NDAs:11

Drugs and US Patents for Amring Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amring Pharms MESALAMINE mesalamine SUPPOSITORY;RECTAL 208362-001 Jun 21, 2019 AB RX No No   Start Trial   Start Trial
Amring Pharms LYSTEDA tranexamic acid TABLET;ORAL 022430-001 Nov 13, 2009 AB RX Yes Yes 8,487,005   Start Trial Y   Start Trial
Amring Pharms LYSTEDA tranexamic acid TABLET;ORAL 022430-001 Nov 13, 2009 AB RX Yes Yes 8,273,795   Start Trial   Start Trial
Amring Pharms LYSTEDA tranexamic acid TABLET;ORAL 022430-001 Nov 13, 2009 AB RX Yes Yes 8,791,160   Start Trial Y   Start Trial
Amring Pharms NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 210989-001 Aug 22, 2018 AP RX No No   Start Trial   Start Trial
Amring Pharms BROMFENAC SODIUM bromfenac sodium SOLUTION/DROPS;OPHTHALMIC 202030-001 Jan 9, 2013 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for AMRING PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 650 mg ➤ Subscribe 2011-05-24

Supplementary Protection Certificates for Amring Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1586316 11C0031 France   Start Trial PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1586316 122011100019 Germany   Start Trial PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1429780 SPC/GB12/058 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1586316 2011C/027 Belgium   Start Trial PRODUCT NAME: BROMFENAC; AUTHORISATION NUMBER AND DATE: EU/1/11/692/001 20110523
0809498 SPC/GB10/012 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0364417 9690031-1 Sweden   Start Trial PRODUCT NAME: LATANOPROST
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
McKinsey
Express Scripts
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.